Literature DB >> 9523988

Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy.

F Kratz1, U Beyer, T Roth, N Tarasova, P Collery, F Lechenault, A Cazabat, P Schumacher, C Unger, U Falken.   

Abstract

One strategy for improving the antitumor selectivity and toxicity profile of antitumor agents is to design drug carrier systems employing suitable carrier proteins. Thus, thiolated human serum transferrin was conjugated with four maleimide derivatives of doxorubicin that differed in the stability of the chemical link between drug and spacer. Of the maleimide derivatives, 3-maleimidobenzoic or 4-maleimidophenylacetic acid was bound to the 3'-amino position of doxorubicin through a benzoyl or phenylacetyl amide bond, and 3-maleimidobenzoic acid hydrazide or 4-maleimidophenylacetic acid hydrazide was bound to the 13-keto position through a benzoyl hydrazone or phenylacetyl hydrazone bond. The acid-sensitive transferrin conjugates prepared with the carboxylic hydrazone doxorubicin derivatives exhibited an inhibitory efficacy in the MDA-MB-468 breast cancer cell line and U937 leukemia cell line comparable to that of the free drug (employing the BrdU (5-bromo-2'-deoxyuridine) incorporation assay and tritiated thymidine incorporation assay, respectively, IC50 approximately 0.1-1 mM), whereas conjugates with the amide derivatives showed no activity. Furthermore, antiproliferative activity of the most active transferrin conjugate (i.e. the conjugate containing a benzoyl hydrazone link) was demonstrated in the LXFL 529 lung carcinoma cell line employing a sulforhodamine B assay. In contrast to in vitro studies in tumor cells, cell culture experiments performed with human endothelial cells (HUVEC) showed that the acid-sensitive transferrin conjugates of doxorubicin were significantly less active than free doxorubicin (IC50 values approximately 10-40 higher by the BrdU incorporation assay), indicating selectivity of the doxorubicin-transferrin conjugates for tumor cells. Fluorescence microscopy studies in the MDA-MB-468 breast cancer cell showed that free doxorubicin accumulates in the cell nucleus, whereas doxorubicin of the transferrin conjugates is found localized primarily in the cytoplasm. The differences in the intracellular distribution between transferrin-doxorubicin conjugates and doxorubicin were confirmed by laser scanning confocal microscopy in LXFL 529 cells after a 24 h incubation that revealed an uptake and mode of action other than intercalation with DNA. The relationship between stability, cellular uptake, and cytotoxicity of the conjugates is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523988     DOI: 10.1021/js970246a

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.

Authors:  U Beyer; B Rothern-Rutishauser; C Unger; H Wunderli-Allenspach; F Kratz
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 3.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

4.  Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.

Authors:  Sumit Majumdar; Bimo A Tejo; Ahmed H Badawi; David Moore; Jeffrey P Krise; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

Review 5.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

6.  Quantitative subcellular study of transferrin receptor-targeted doxorubicin and its metabolite in human breast cancer cells.

Authors:  Jinhui Xu; Yuan Sheng; Feifei Xu; Ying Yu; Yun Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-22       Impact factor: 2.441

7.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

8.  Discovery of a Highly Conserved Peptide in the Iron Transporter Melanotransferrin that Traverses an Intact Blood Brain Barrier and Localizes in Neural Cells.

Authors:  Chaahat S B Singh; Brett A Eyford; Thomas Abraham; Lonna Munro; Kyung Bok Choi; Mark Okon; Timothy Z Vitalis; Reinhard Gabathuler; Chieh-Ju Lu; Cheryl G Pfeifer; Mei Mei Tian; Wilfred A Jefferies
Journal:  Front Neurosci       Date:  2021-06-02       Impact factor: 4.677

9.  Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.

Authors:  Artavazd Arumov; Piumi Y Liyanage; Roger M Leblanc; Jonathan H Schatz; Asaad Trabolsi; Evan R Roberts; Lingxiao Li; Braulio C L B Ferreira; Zhen Gao; Yuguang Ban; Austin D Newsam; Melissa W Taggart; Francisco Vega; Daniel Bilbao
Journal:  Cancer Res       Date:  2020-11-11       Impact factor: 13.312

10.  A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier.

Authors:  Delara Karkan; Cheryl Pfeifer; Timothy Z Vitalis; Gavin Arthur; Maki Ujiie; Qingqi Chen; Sam Tsai; Gerrasimo Koliatis; Reinhard Gabathuler; Wilfred A Jefferies
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.